Register for real-time alerts, custom portfolio, and market movers
| Name | Symbol | Market | Type |
|---|---|---|---|
| BioNTech SE | NASDAQ:BNTX | NASDAQ | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 4.90 | 4.53% | 113.13 | 109.00 | 114.00 | 114.3199 | 107.41 | 107.87 | 1,185,689 | 23:00:00 |
From Nov 2023 to Nov 2024
By Josh Beckerman
BioNTech shares were down 3.4% after the company projected 2024 revenue of about 3 billion euros ($3.28 billion), compared with the average estimate of $4.11 billion from analysts polled by FactSet.
The stock was recently at $108.04 and is down about 29% over the past 52 weeks.
The immunotherapy company expects topline growth in 2025.
BioNTech, widely known for its Covid-19 vaccine, has been expanding in areas including oncology. The company said Tuesday that "late-stage trials are ongoing in multiple oncology indications, and we plan to have ten or more potentially registrational trials in our pipeline by the end of 2024."
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
January 09, 2024 14:42 ET (19:42 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
1 Year BioNTech Chart |
1 Month BioNTech Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
